Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D S Small

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 1, 1995
Acitretin elimination in Sprague-Dawley rats pretreated with phenobarbital or beta-naphthoflavoneD S Small, P J McNamara
Journal of Pharmaceutical Sciences|May 1, 1994
Hepatic enzyme induction potential of acitretin in male and female Sprague-Dawley ratsD S Small, P J McNamara
Journal of the American Statistical Association|June 22, 2023
Matching One Sample According to Two Criteria in Observational StudiesB Zhang, D S Small, K B Lasater, et al.
Journal of Clinical Pharmacy and Therapeutics|September 12, 2009
Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver diseaseD S Small, N A Farid, Y G Li, et al.
Clinical Pharmacology and Therapeutics|March 16, 2007
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differentlyN A Farid, C D Payne, D S Small, et al.
Current Medical Research and Opinion|June 18, 2009
Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjectsN A Farid, J A Jakubowski, C D Payne, et al.
Journal of Thrombosis and Haemostasis : JTH|November 10, 2012
Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementationM U Zafar, C Santos-Gallego, D A Vorchheimer, et al.
Journal of Clinical Pharmacy and Therapeutics|September 12, 2009
Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal diseaseD S Small, R E Wrishko, C S Ernest, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 1, 1995
Acitretin elimination in Sprague-Dawley rats pretreated with phenobarbital or beta-naphthoflavoneD S Small, P J McNamara
Journal of Pharmaceutical Sciences|May 1, 1994
Hepatic enzyme induction potential of acitretin in male and female Sprague-Dawley ratsD S Small, P J McNamara
Journal of the American Statistical Association|June 22, 2023
Matching One Sample According to Two Criteria in Observational StudiesB Zhang, D S Small, K B Lasater, et al.
Journal of Clinical Pharmacy and Therapeutics|September 12, 2009
Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver diseaseD S Small, N A Farid, Y G Li, et al.
Clinical Pharmacology and Therapeutics|March 16, 2007
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differentlyN A Farid, C D Payne, D S Small, et al.
Current Medical Research and Opinion|June 18, 2009
Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjectsN A Farid, J A Jakubowski, C D Payne, et al.
Journal of Thrombosis and Haemostasis : JTH|November 10, 2012
Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementationM U Zafar, C Santos-Gallego, D A Vorchheimer, et al.
Journal of Clinical Pharmacy and Therapeutics|September 12, 2009
Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal diseaseD S Small, R E Wrishko, C S Ernest, et al.
Pageof 1